PharmaShots | Incisive News in 3 Shots

Subscribe Now

FOCUS Trial

AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease

AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease

August 26, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us